All results
1 results
-
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a) (20226313)
This study is being done to learn more about olpasiran (AMG 890) in people with cardiovascular disease and elevated Lp(a). It will see if olpasiran (AMG 890)…
- Ages
- 18 Years - 85 Years
- Sexes
- All